Literature DB >> 3423305

Gastrointestinal morbidity of adjuvant radiotherapy in stage I malignant teratoma of the testis.

C R Hamilton1, A Horwich, J M Bliss, M J Peckham.   

Abstract

Between January 1963 and December 1983, 248 patients with stage I teratoma were managed by the Testicular Tumour Unit of the Royal Marsden Hospital (RMH). Before 1979, these patients were treated with adjuvant irradiation to the abdominal and pelvic lymph nodes (142 patients) to a mid-plane dose of 40 Gy in 20 fractions over 4 weeks. In 1979, a surveillance policy was adopted (106 patients) and relapsing patients treated with chemotherapy. By 2 years post-orchidectomy, seven patients (4.9%) in the irradiated group developed duodenal ulceration compared to none in the surveillance group (p = 0.05). A past medical history of duodenal ulcer was a significant risk factor for ulceration after radiotherapy (p = 0.04) whereas a past history of abdominal surgery was not (p = 0.8). It is concluded that adjuvant radiotherapy for stage I teratoma may increase the risk of peptic ulceration.

Entities:  

Mesh:

Year:  1987        PMID: 3423305     DOI: 10.1016/s0167-8140(87)80049-x

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

1.  Retroperitoneal lymph node dissection for high-risk stage I and stage IIA seminoma.

Authors:  Zaza Mezvrishvili; Laurent Managadze
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

Review 2.  Pathobiology, irradiation dosimetric parameters and therapy of radiation-induced gastric damage: a narrative review.

Authors:  Michael J McKay; Richard Foster
Journal:  J Gastrointest Oncol       Date:  2021-12

3.  Duodenal ulcer: a model of impaired mucosal defence.

Authors:  R H Gompertz; A S Michalowski; W K Man; J Spencer; J H Baron
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

4.  Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer.

Authors:  Kento Takatori; Kazuki Terashima; Rihito Yoshida; Aya Horai; Shinya Satake; Takayuki Ose; Naoto Kitajima; Yoshikazu Kinoshita; Yusuke Demizu; Nobukazu Fuwa
Journal:  J Gastroenterol       Date:  2013-07-12       Impact factor: 7.527

5.  Testicular seminoma: 20-year experience at the Northern Israel Oncology Center (1968-1988).

Authors:  M Stein; M Steiner; B Moshkowitz; D Sapir; I Kessel; A Kuten
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

6.  Surveillance following orchidectomy for stage I testicular seminoma.

Authors:  A Horwich; N Alsanjari; R A'Hern; J Nicholls; D P Dearnaley; C Fisher
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

7.  An analysis of surveillance for stage I combined teratoma--seminoma of the testis.

Authors:  R Thomas; D Dearnaley; J Nicholls; A Norman; S Sampson; A Horwich
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

8.  Modelling duodenum radiotherapy toxicity using cohort dose-volume-histogram data.

Authors:  Daniel L P Holyoake; Marianne Aznar; Somnath Mukherjee; Mike Partridge; Maria A Hawkins
Journal:  Radiother Oncol       Date:  2017-06-06       Impact factor: 6.280

9.  Long-term somatic side-effects and morbidity in testicular cancer patients.

Authors:  N Aass; S Kaasa; E Lund; O Kaalhus; M S Heier; S D Fosså
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.